WADA prohibited list raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-20. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Former SNP chief executive Peter Murrell appears before Edinburgh Sheriff Court charged with embezzlement, while his estranged wife, former Nicola Sturgeon, is told she will face no further action in the police investigation into SNP finances. Kemi Badenoch launches the Conservative local election campaign at an event in Buckinghamshire. Jo Coburn announces her departure from the BBC and as host of the programme BBC Politics Live. The 2025 City of London Corporation election is held in the City of London. 21 March – SNP MSP Fergus Ewing announces he will not stand for the party at the 2026 Holyrood election, but may run as an independent. Leaked messages deepen the row between Nigel Farage and Rupert Lowe. Rachel Reeves pledges no "tax and spend" in her spring statement. 22 March – The UK government is reported to be considering establishing "return hubs" for failed asylum seekers in the Balkans. 23 March – Chancellor Rachel Reeves confirms plans to reduce government running costs by 15% by the end of the decade. Steve Witkoff, the US special envoy to the Middle East, dismisses Starmer's plan for an international peacekeeping force to support a ceasefire in Ukraine as "a posture and a pose". 25 March – The UK government confirms it is ending a contract with Stay Belvedere Hotels to provide places for asylum seekers after an audit identified concerns about the firm's performance. A report by Jacqueline Perry KC finds "credible evidence" Rupert Lowe and his staff mistreated two female team members in ways that "seem to amount to harassment".
== Science and technology == MSI Barcode, a continuous numeric barcode symbology Microsatellite instability, an abnormality of DNA Mass spectrometry imaging, a technique used in mass spectrometry Mass sociogenic illness, the rapid spread of physical symptoms of illness among the members of a group with no physical or infectious cause Magnetic source imaging, magnetoencephalography combined with magnetic resonance imaging Multispectral imaging, the capture of multiple, specific wavelengths in the electromagnetic spectrum Musculoskeletal injury, damage of muscular or skeletal systems which is usually due to a strenuous activity
After 1990s new memoirs and archival materials have opened up the study of espionage and intelligence during the Cold War. Scholars are reviewing how its origins, its course, and its outcome were shaped by the intelligence activities of the United States, the Soviet Union, and other key countries. Special attention is paid to how complex images of one's adversaries were shaped by secret intelligence that is now publicly known.
=== Biosynthesis === Ricin is synthesized in the endosperm of castor oil plant seeds. The ricin precursor protein is 576 amino acid residues in length and contains a signal peptide (residues 1–35), the ricin A chain (36–302), a linker peptide (303–314), and the ricin B chain (315–576). The N-terminal signal sequence delivers the prepropolypeptide to the endoplasmic reticulum (ER) and then the signal peptide is cleaved off. Within the lumen of the ER the propolypeptide is glycosylated and a protein disulfide isomerase catalyzes disulfide bond formation between cysteines 294 and 318. The propolypeptide is further glycosylated within the Golgi apparatus and transported to protein storage bodies. The propolypeptide is cleaved within protein bodies by an endopeptidase to produce the mature ricin protein that is composed of a 267 residue A chain and a 262 residue B chain that are covalently linked by a single disulfide bond.
=== Photodegradation === Additionally, DBNPA is prone to light-induced degradation, especially when exposed to ultraviolet (UV) radiation. Photocatalytic breakdown leads to debromination and the formation of less reactive intermediates, further accelerating its degradation in aqueous systems.
Sources: en.wikipedia.org
Someone with a good memory of the conversation once told me how Lord Carrington, then one of the "mediators" of the incipient post-Yugoslavia war, came to the conclusion that Slobodan Milosevic was a highly dangerous man. Well-disposed toward Serbia (as the British establishment has always been), Carrington told the late dictator that he understood Serb concerns about significant Serbian minorities in Bosnia and Croatia. But why did Milosevic also insist on exclusive control over Kosovo, where the Albanian population was approximately 90 percent? "That," replied Milosevic coldly, "is for historical reasons." It's a shame, in retrospect, that it took us so long to diagnose the pathology of Serbia's combination of arrogance and self-pity, in which what is theirs is theirs and what is anybody else's is negotiable. After the war, Hitchens supported Kosovo's independence and criticized the burning of the US Embassy in Belgrade as a response to it:
This would be easier to log data and keep it accurate since it would be digital rather than in paper form. The clinical data repository is not without its weaknesses, however. Since they usually don't integrate with other non-clinical sources, following patient treatment across the care continuum becomes very difficult. In turn, tracking the true cost per case for each patient isn't feasible. IT teams spend most of their time gathering and compiling data instead of interpreting information and finding opportunities for cutting costs and improving patient care.
== Side effects == At high doses there are strong CNS effects and the atropine at such high doses causes typical anticholinergic side effects, such as anxiety, dysphoria, and delirium. Excessive use or overdose causes constipation and can promote development of megacolon as well as classic symptoms of overdose including potentially lethal respiratory depression. In the 1990s its use in children was restricted in many countries due to the CNS side effects, which included anorexia, nausea and vomiting, headache, drowsiness, confusion, insomnia, dizziness, restlessness, euphoria and depression.
== Contraindications == Caution is required in patients having closed angle glaucoma and in patients with a predisposition to urinary retention as the medication exhibits a relatively small anticholinergic effect. Dose adjustment is required in people who have chronic kidney disease. Liver injury has also been reported. Pizotifen treatment should be discontinued if there is any clinical evidence of liver dysfunction during treatment. Caution is advised in patients having a history of epilepsy. Withdrawal symptoms like depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decrease have been reported following abrupt cessation of pizotifen. Pizotifen is contraindicated in patients who suffer from hypersensitivity to any of its components or have gastric outlet obstruction, angle-closure glaucoma, and difficulty urinating. In addition, women who are pregnant should not take pizotifen.
Lori stated that he would be taking a sabbatical from the program until he recovers. She blamed the stroke on Bakker's hard work on his show and wrote that he had described the criticism against him as "the most vicious attack that he has ever experienced". Bakker returned to his program for the first time following his stroke on July 8, 2020. On June 23, 2021, Missouri Attorney General Eric Schmitt announced the settlement of the state's lawsuit against Bakker. Bakker and Morningside Church would be prohibited from saying silver solution could "diagnose, prevent, mitigate, treat, or cure any disease or illness". Restitution of about $157,000 would also be paid to those who bought silver solution between February 12, 2020, and March 10, 2020.
Sources: en.wikipedia.org
To date, at least, there is little sign of a serious effort to forge a meaningful anti-American alliance ... From the traditional perspective of balance-of-power theory, this situation is surely an anomaly. Power in the international system is about as unbalanced as it has ever been, yet balancing tendencies are remarkably mild. It is possible to find them, but one has to squint pretty hard to do it.
Catching a chameleon: mRNA can be engineered to overcome cancer evolution, essay by Elias Sayour, a pediatric oncologist. Science (journal), 2 Apr 2026 "Five things you need to know about: mRNA vaccines". Horizon. Archived from the original on 4 April 2020. Retrieved 17 November 2020. "RNA vaccines: an introduction". PHG Foundation. University of Cambridge. "Understanding mRNA COVID-19 Vaccines". Centers for Disease Control and Prevention. 4 January 2022. Kolata G, Mueller B (15 January 2022). "Halting Progress and Happy Accidents: How mRNA Vaccines Were Made". The New York Times. M.I.T. Lecture 10: Kizzmekia Corbett, Vaccines" on YouTube
Novich, wrote: "Trainers of the old school who supplied treatments which had cocaine as their base declared with assurance that a rider tired by a six-day race would get his second breath after absorbing these mixtures." John Hoberman, a professor at the University of Texas in Austin, Texas, said six-day races were "de facto experiments investigating the physiology of stress as well as the substances that might alleviate exhaustion."
Afterwards, the two leaders and their wives proceeded to the White House Rose Garden for a Military Review. The United States Air Force Honor Guard presenting American and Chinese flags were positioned upon the roof of West Wing Colonnade; BBC News observed it is "highly unusual to see uniformed soldiers standing at attention above the Oval Office" and remarked the welcome for Xi "has far exceeded the welcome given other visiting heads of state in Trump's second term". The 15‑minute presentation included the Old Guard Fife and Drum Corps dressed in Continental Army dress uniforms, the US Marine Corps Silent Drill Platoon and the United States Marine Drum and Bugle Corps performances with a flyover finale featuring a B-2 Spirit and four F-22 Raptors. Cai Qi, Wang Yi, JD Vance and his wife Usha Vance, and Ivanka Trump were also present at the ceremony. Afterwards, the two leaders and their respective contingents went to the Oval Office to start their meeting. which lasted for 90 minutes. Xi was accompanied by CCP General Office Director Cai Qi, Vice Premier He Lifeng, Central Foreign Affairs Commission Office Director and Foreign Minister Wang Yi, National Development and Reform Commission Director Zheng Shanjie, and Minister of Commerce Wang Wentao. Trump was joined by Vice President JD Vance, Secretary of State Marco Rubio, Secretary of Treasury Scott Bessent, White House Chief of Staff Susie Wiles and Secretary of Defense Pete Hegseth.
GeneDx's biopharma business focuses on leveraging GeneDx Infinity to provide partners with access to molecularly confirmed genomic data, longitudinal patient information, and curated phenotypic data to support drug discovery, clinical development, real-world evidence generation and other therapeutic development needs. By combining large-scale sequencing data with clinical and phenotypic context, the company aims to accelerate rare disease research and improve the efficiency and success rate of biopharmaceutical development programs.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.